New Zealand markets open in 3 hours 53 minutes

BIIB Jan 2023 310.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
119.320.00 (0.00%)
As of 12:22PM EDT. Market open.
Full screen
Previous close119.32
Open119.32
Bid92.00
Ask98.80
Strike310.00
Expiry date2023-01-20
Day's range119.32 - 119.32
Contract rangeN/A
Volume2
Open interest70
  • Motley Fool

    Is This Biotech Stock a Bad News Buy?

    Shares of biotech giant Biogen (NASDAQ: BIIB) have dropped by 40% in the past year, easily underperforming the broader market over this period. The drugmaker has encountered many headwinds related to its controversial Alzheimer's disease drug, Aduhelm. Recapping the entire Aduhelm saga would take far more space than we have here.

  • Zacks

    Biogen (BIIB) Lecanemab Gets FDA Priority Tag for Alzheimer's

    The FDA sets a target date of Jan 6, 2023 for Biogen (BIIB) and partner Eisai's regulatory filing, which seeks accelerated approval for lecanemab to treat Alzheimer's disease (AD).

  • Business Wire

    Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform

    CAMBRIDGE, Mass. & NEW YORK, June 22, 2022--Biogen (NASDAQ:BIIB) and Happify Health (www.HappifyHealth.com), the Intelligent Healing Company™, today announced a collaboration to provide a digital solution for patient education and engagement, powered by artificial intelligence (AI), to support people living with multiple sclerosis (MS). Through this collaboration, Biogen and Happify Health will help people with MS manage their care journey, improve their wellbeing, learn about treatment options,